ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
ABBOTT LABORATORIES
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 28, 2026
$104.06−0.83 (-0.79%)
Close on Oct 19, 2026
- Market cap
- $181.80B
- P/E (TTM)
- 29.0
- Dividend yield
- 2.31%
Share price
−$24.48 (−19.04%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
ABBOTT LABORATORIES grew revenue 6.6% to $45.13B over the twelve months to Mar 31, 2026. Operating income rose 8.0% to $7.71B, moving the operating margin from 16.8% to 17.1%. Free cash flow was $7.38B, up 10.8% from a year earlier.
Revenue
$45.13B
+6.6% vs. a year earlier
Operating income
$7.71B
+8.0% vs. a year earlier
Free cash flow
$7.38B
+10.8% vs. a year earlier
EPS, diluted
$3.59
-53.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2026
Valuation
- Market cap
- $181.80B
- P/E ratio
- 29.0
- Price to sales
- 4.03
- Price to book
- 3.49
- Dividend yield
- 2.31%
- Free cash flow yield
- 4.06%
Fundamentals
- Revenue
- $45.13B
- Net income
- $6.28B
- EPS, diluted
- $3.59
- Free cash flow
- $7.38B
- Book value per share
- $29.80
- Diluted shares
- 1.75B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$45.13B+6.6% YoY
Gross profit
$25.39B+7.4% YoY
Operating income
$7.71B+8.0% YoY
Net income
$6.28B-53.5% YoY
EPS, diluted
$3.59-53.5% YoY
Free cash flow
$7.38B+10.8% YoY
Reported periodTrailing twelve months